Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Renal denervation
13 evidence topics · 11 sources
FDA approval: Symplicity Spyral radiofrequency system
FDA approval: Paradise ultrasound system
Medicare coverage with evidence development: CMS national coverage decision
CMS assessment of the evidence
Place of renal denervation in resistant hypertension: 2025 AHA/ACC guideline
Patient selection for renal denervation: 2025 AHA/ACC guideline
Renal denervation recommendation and limitations: 2024 ESC guideline
Renal denervation as an additive or alternative option: 2023 ESH guideline
Ultrasound renal denervation in resistant hypertension: RADIANCE-HTN TRIO trial
“Eligible patients were switched to a once daily, fixed-dose, single-pill combination of a calcium channel blocker, an angiotensin receptor blocker, and a thiazide diuretic.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between March 11, 2016, and March 13, 2020, 989 participants were enrolled and 136 were randomly assigned to renal denervation (n=69) or a sham procedure (n=67).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Renal denervation reduced daytime ambulatory systolic blood pressure more than the sham procedure (-8·0 mm Hg [IQR -16·4 to 0·0] vs -3·0 mm Hg [-10·3 to 1·8]; median between-group difference -4·5 mm Hg [95% CI -8·5 to -0·3]; adjusted p=0·022)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ultrasound renal denervation without medications: RADIANCE II trial
“Among 1038 eligible patients, 150 were randomized to ultrasound renal denervation and 74 to a sham procedure (mean age, 55 years [SD, 9.3 years]; 28.6% female; and 16.1% self-identified as Black or African American). The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No major adverse events were reported in either group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency renal denervation with medications at 6 months: SPYRAL HTN-ON MED trial
“The treatment difference in the mean 24-hour ambulatory systolic BP from baseline to 6 months between the RDN group (n = 206; -6.5 ± 10.7 mm Hg) and sham control group (n = 131; -4.5 ± 10.3 mm Hg) was -1.9 mm Hg (95% CI: -4.4 to 0.5 mm Hg; P = 0.12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RDN was associated with a reduction in office systolic BP compared with sham control at 6 months (adjusted treatment difference: -4.9 mm Hg; P = 0.0015).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency renal denervation with medications at 24 months: SPYRAL HTN-ON MED trial
“At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P=0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P=0.0034) compared with sham controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinically adverse events were rare, with no instances of renal artery stenosis through 24 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency renal denervation with medications at 36 months: SPYRAL HTN-ON MED pilot cohort
“At 36 months, the ambulatory systolic blood pressure reduction was -18·7 mm Hg (SD 12·4) for the renal denervation group (n=30) and -8·6 mm Hg (14·6) for the sham control group (n=32; adjusted treatment difference -10·0 mm Hg, 95% CI -16·6 to -3·3; p=0·0039).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote